Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis | ||
Cardiovascular Research Prove Journal | ||
Volume 3, Issue 1, June 2019 PDF (34.72 K) | ||
Document Type: Abstracts | ||
DOI: 10.21608/cvrepj.2019.351824 | ||
Abstract | ||
Pristimerin (Pris) is triterpenoid compound with many biological effects. Until now, nothing is known about its effect on doxorubicin (DOX)-induced cardiotoxicity. Hence, this study investigated the impact of Pris on DOX-induced cardiotoxic effects. | ||
Statistics Article View: 67 PDF Download: 29 |